Oncomatryx Biopharma
Pedro Esnaola is an accomplished professional with extensive experience in the biopharmaceutical sector and various leadership roles. As President of Quimatryx since April 2015, Pedro spearheads the discovery and development of novel drugs targeting epigenetic factors in cancer treatment. Additionally, Pedro serves as CPAO at Oncomatryx Biopharma, focusing on precision drugs that disrupt the tumor microenvironment. Formerly a Consul Honorary for Slovenia and holding advisory positions at ZAISA and ORTZIBIA, Pedro's expertise extends across logistics and governing organizations, including leadership roles at the Gipuzkoa Chamber of Commerce and the Basque Health Cluster. Pedro holds a Bachelor's degree in Economics from Universidad del País Vasco and an Executive MBA from the University of Deusto.
This person is not in any teams
Oncomatryx Biopharma
Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment.Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma.Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumorinvasiveness, drug resistance and immunosuppression.Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.